CD274 and non-small cell lung carcinoma: There are ongoing clinical trials in patients with advanced NSCLC, in which classical anti-PD-1 or anti-PD-L1 antibodies are attempted to be combined with antibodies against ICOS (inducible T-cell costimulator), LAG-3, TIM-3 (T-cell immunoglobulin domain and mucin domain 3), or TIGIT [43,44,45,46,47].